Alopecia epidemiology and demographics

Revision as of 09:41, 12 December 2020 by Nnabude (talk | contribs)
Jump to navigation Jump to search

Alopecia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alopecia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Laser Therapy

Concealing Hair Loss

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alopecia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alopecia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alopecia epidemiology and demographics

CDC on Alopecia epidemiology and demographics

Alopecia epidemiology and demographics in the news

Blogs on Alopecia epidemiology and demographics

Directions to Hospitals Treating Alopecia

Risk calculators and risk factors for Alopecia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD

Overview

The epidemiology and demographics of alopecia varies by age, race, sex, and health status.

Alopecia epidemiology and demographics

  • Androgenetic alopecia affects 50% of men and 15% of women, particularly postmenopausal women. [1]
  • In alopecia areata, the prevalence is 0.2% and has no age or sexual predilection. However, it affects white races more than dark races.
  • In telogen effluvium, women are at higher predisposition than men.
  • Tinea capitis has a higher incidence among the pediatric age group and in darker races. [2]
  • Anagen effluvium is more common in cancer patients receiving treatment with chemotherapeutic agents.

References

  1. Rinaldi F, Marzani B, Pinto D, Sorbellini E (2019). "Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata". J Dermatolog Treat. 30 (6): 588–593. doi:10.1080/09546634.2018.1544405. PMID 30513014.
  2. Owczarczyk-Saczonek A, Wygonowska E, Budkiewicz M, Placek W (2019) Serum sickness disease in a patient with alopecia areata and Meniere' disease after PRP procedure. Dermatol Ther 32 (2):e12798. DOI:10.1111/dth.12798 PMID: 30511475

Template:WikiDoc Sources